A Chinese scientist reviewing laboratory equipment

Research news

This section contains news items that were not issued as a press release.

Thursday, 27 March 2014
AstraZeneca and Shenzhen University Health Science Center to collaborate on chronic kidney disease SHANGHAI, CHINA –AstraZeneca today announced a research collaboration with Shenzhen University Health Science Center.
Tuesday, 25 March 2014
New Open Innovation platform launched offering access to Compound Bank and partnering programmes AstraZeneca’s IMED Biotech unit has launched a dedicated website to support an increasing range of open innovation programmes and to better facilitate research collaborations with academia, industry, NGOs and governments.
Thursday, 6 March 2014
AstraZeneca and Korea Health Industry Development Institute to establish oncology research programme AstraZeneca announced today that it has signed a memorandum of understanding (MOU) with the Korea Health Industry Development Institute (KHIDI) to establish an Oncology Research Programme.
Monday, 17 February 2014
AstraZeneca scientists to work alongside researchers at Cancer Research UK Cambridge Institute AstraZeneca today announced that it has entered into a collaboration with the Cancer Research UK (CRUK) Cambridge Institute to temporarily locate up to 60 AstraZeneca scientists in the Institute. The CRUK Cambridge Institute, part of the University of Cambridge, is located on the Cambridge Biomedical Campus, the future site of AstraZeneca’s UK-based global strategic research and development centre and corporate headquarters.
Thursday, 23 January 2014
AstraZeneca and Shanghai Institutes of Biological Sciences announce research collaboration SHANGHAI, CHINA – AstraZeneca today announced the signing of a research collaboration in the area of cardiovascular diseases (CVD) with the Shanghai Institutes of Biological Sciences (SIBS)
Tuesday, 3 December 2013
AstraZeneca and Lieber Institute for Brain Development announce neuroscience collaboration AstraZeneca today announced that it has entered into a two-year research collaboration with the Lieber Institute for Brain Development (LIBD) to use genetics and stem cell biology to discover new drugs for neuropsychiatric and neurodevelopmental disorders such as autism and schizophrenia.
Wednesday, 20 November 2013
Karolinska Institutet appoints Dr. Bo Angelin to lead integrated cardio metabolic center AstraZeneca and the Swedish medical university Karolinska Institutet announced today the appointment of Bo Angelin M.D. Ph.D. to lead their Integrated Cardio Metabolic Center (ICMC) located at the Karolinska Institutet site in Stockholm, Sweden.
Thursday, 14 November 2013
AstraZeneca announces initiation of two additional global studies for BRILINTA (ticagrelor) AstraZeneca today announced plans to conduct two new Phase IIIb clinical studies as part of PARTHENON, the company’s largest clinical trial programme involving over 80,000 patients. The studies are designed to build scientific understanding of BRILINTA® (ticagrelor) tablets in additional high-risk patient populations.
Monday, 4 November 2013
A*STAR and AstraZeneca sign a research collaboration agreement to develop new antimicrobial drugs to combat Gram-negative bacterial infections Two units under Singapore’s Agency for Science, Technology and Research (A*STAR), the Experimental Therapeutics Centre (ETC) and Exploit Technologies Pte Ltd (ETPL) have signed a joint research collaboration agreement with global biopharmaceutical company AstraZeneca (AZ), to develop new drugs to treat Gram-negative bacterial infections. Such infections are believed to cause two thirds of all hospital acquired infection deaths.
Thursday, 17 October 2013
AstraZeneca announces ‘Open Innovation’ research collaboration with Taiwan’s research program for biopharmaceuticals AstraZeneca and Taiwan’s National Research Program for Biopharmaceuticals (NRPB) today announced a collaborative programme to support academic research proposals using ‘open innovation’ as a catalyst for drug discovery